Latest Payments News

Tempest Minerals has agreed to sell its Yalgoo Project to Capricorn Metals for $4.5 million in cash and shares, with additional payments tied to future discoveries and production milestones. The deal, expected to complete in early 2026, leaves Tempest retaining iron rights on key tenements while refocusing on other Western Australian assets.

Cavalier Resources has signed a landmark Native Title Agreement with the Wangkatja Aboriginal Corporation, clearing a major hurdle for the Crawford Gold Project. Alongside this, an updated Pre-Feasibility Study confirms robust economics underpinning near-term production.

Australia and New Zealand Banking Group Limited (ANZ) has announced a quarterly distribution of AUD 1.2013 per security on its CAP NOTE AN3PK, payable in March 2026. The payment is 70% franked and subject to standard conditions and ANZ’s discretion.

Centuria Capital Group has announced a 5.20 cents per stapled security interim distribution for December 2025, combining a fully franked dividend and trust distribution. Notably, the Distribution Reinvestment Plan is suspended for this payment.

Centuria Capital Group has announced an ordinary fully franked dividend of AUD 0.052 per security for the half-year ending December 2025, signaling steady income for investors.

S2 Resources has completed the sale of its Fosterville exploration licence to Agnico Eagle for A$17 million, significantly strengthening its cash position and enabling a renewed focus on exploration projects in New South Wales and Western Australia.

State Street Global Advisors has announced estimated distributions for its suite of SPDR ETFs for the period ending December 31, 2025, providing investors with key income expectations across Australian and international equities as well as fixed income funds.

Regal Investment Fund has announced an estimated ordinary dividend of AUD 0.12 per unit for the half-year ending December 2025, alongside a full Dividend Reinvestment Plan available to eligible investors.

Pure One Corporation Limited is set to exit its 40% stake in Turquoise Group for AUD 5 million, securing a substantial profit and refocusing on its core clean energy ventures.

BioMarin Pharmaceutical’s acquisition of Amicus Therapeutics for US$4.8 billion includes Dimerix’s US licensing agreement, promising significant milestone payments and royalties. This deal strengthens Dimerix’s position as it advances its Phase 3 kidney disease therapy.

Aurizon has lodged a proposed ten-year Network Access Undertaking with the Queensland Competition Authority, aiming to secure long-term certainty and enhanced operational incentives for the Central Queensland Coal Network.

Stockland has announced an estimated ordinary dividend of AUD 0.09 per security for the six months ending December 2025, payable in February 2026, alongside a Dividend Reinvestment Plan offering a 1% discount.